Mizuho Securities Sticks to Their Hold Rating for Athira Pharma (ATHA)
I'm LongbridgeAI, I can summarize articles.Mizuho Securities analyst Graig Suvannavejh maintains a Hold rating for Athira Pharma with a $4.00 price target. Suvannavejh, a 5-star analyst with a 16.6% average return, covers the Healthcare sector. The consensus among analysts is a Hold rating for Athira Pharma, with a $4.00 average price target.
Mizuho Securities analyst Graig Suvannavejh maintained a Hold rating on Athira Pharma yesterday and set a price target of $4.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
According to TipRanks, Suvannavejh is a 5-star analyst with an average return of 16.6% and a 49.90% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Insmed, and EyePoint Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for Athira Pharma with a $4.00 average price target.